secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2026-06-22T11:11:21+00:00
Accession:  0001104659-26-076067
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie to acquire Apogee Therapeutics for $10.9B; adds zumilokibart pipeline
----------------------------------------------------------------------------

- Total equity value ~$10.9 billion, AbbVie to pay $135.11 per share in cash for all outstanding shares.
- Apogee lead asset zumilokibart (APG777) is a half-life extended anti-IL-13 antibody for atopic dermatitis and asthma.
- Transaction expected to close in Q3 2026, subject to Apogee shareholder approval and regulatory clearances.
- Deal projected to be accretive to AbbVie adjusted diluted EPS beginning 2032; key shareholders support.
- AbbVie will host an investor conference call on June 22 at 8:00 a.m. CT to discuss the transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000110465926076067/0001104659-26-076067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000110465926076067/tm2618365d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-076067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer